AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fries, B. C.
Right arrow Articles by Casadevall, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fries, B. C.
Right arrow Articles by Casadevall, A.
Antimicrobial Agents and Chemotherapy, January 2005, p. 350-357, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.350-357.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Effects of Antifungal Interventions on the Outcome of Experimental Infections with Phenotypic Switch Variants of Cryptococcus neoformans

Bettina C. Fries,1* Emily Cook,1 Xiabo Wang,1 and Arturo Casadevall1,2

Departments of Medicine,1 Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York2

Received 17 June 2004/ Returned for modification 3 August 2004/ Accepted 28 September 2004

In cryptococcal infection, phenotypic switching from a smooth to a mucoid variant can occur in vivo, producing variants with enhanced virulence that are subsequently selected and affect the outcome of infection. Here, we demonstrate that antifungal treatment of the chronically infected host can promote this phenomenon. Amphotericin B treatment reduces fungal burden less effectively in mucoid variant-infected than in smooth variant-infected mice. Consequently, amphotericin B treatment resulted in a more pronounced prolongation of survival in smooth variant-infected than in mucoid variant-infected mice (20 versus 42 days; P < 0.05). Administration of anticapsular monoclonal antibody mediated better protection in smooth variant-infected than in mucoid variant-infected mice, although a protective effect was not consistently observed at all doses. Most interestingly, both antifungal drug therapy and administration of anticapsular monoclonal antibody promoted the selection of mucoid variants in smooth variant-infected mice, a phenomenon manifested by a statistically higher percentage of mucoid colonies in smooth variant-infected mice than in nontreated control mice. This finding suggests that both chemotherapeutic and immunological antifungal interventions may promote the selection of the more virulent mucoid variant, which could affect the outcome of infection in chronically infected hosts.


* Corresponding author. Mailing address: Department of Medicine, Albert Einstein College of Medicine, Golding 702, 1300 Morris Park Ave., Bronx, New York 10461. Phone: (718) 430-2365. Fax: (718) 430-8701. E-mail: fries{at}aecom.yu.edu.


Antimicrobial Agents and Chemotherapy, January 2005, p. 350-357, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.350-357.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.